Quick Answer
Dogwood Therapeutics, Inc. reported Operating Income Loss of -$27.97 million for the year ending 2025.
- Dogwood Therapeutics, Inc. showed a decrease of -128.7% in Operating Income Loss from 2024 to 2025.
- This data is from Dogwood Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$382.6 thousand | Q2 2020: -$538.4 thousand | Q3 2020: -$2.66 million | Q1 2021: -$3.06 million | Q2 2021: -$4.28 million | Q3 2021: -$4.11 million | Q1 2022: -$3.96 million | Q2 2022: -$3.67 million | Q3 2022: -$2.59 million | Q1 2023: -$1.56 million | Q2 2023: -$1.48 million | Q3 2023: -$1.27 million | Q1 2024: -$1.31 million | Q2 2024: -$1.07 million | Q3 2024: -$2.30 million | Q1 2025: -$4.43 million | Q2 2025: -$3.92 million | Q3 2025: -$15.81 million.
- Over the full 6 years of available data (2020 to 2025), Dogwood Therapeutics, Inc.'s Operating Income Loss has declined by 179.5%.
- Historical annual values: Fiscal year 2025: -$27.97 million | Fiscal year 2024: -$12.23 million | Fiscal year 2023: -$5.45 million | Fiscal year 2022: -$12.32 million | Fiscal year 2021: -$15.64 million | Fiscal year 2020: -$10.01 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: